Cancer Tumor Boards in China: How MDT Guides Treatment

Learn how cancer tumor boards review evidence, record options and uncertainty, involve patient preferences and turn an MDT recommendation into action.

Key takeaways

A tumour board is a treatment-planning meeting where cancer clinicians and other specialists review selected cases together.[1] Booking several appointments on the same day is a different thing.
What you actually want out of it is a record tied to your case: the question asked, the evidence reviewed, who was in the room, the options weighed, the recommendation, the uncertainty and who owns the next step.
Patients usually do not sit in. Afterwards a named clinician has to walk through the recommendation, the alternatives and the trade-offs, and bring the patient’s preferences into the final decision.[4][5]
“Consensus” does not mean certainty. Sometimes the team lands on a conditional plan, asks for more evidence or writes down more than one reasonable option.
MDT discussion can improve coordination, but the label alone guarantees nothing about staging accuracy, timeliness or outcomes. Look at what went into the discussion and whether the plan actually happened.

Full guide

No single specialty holds all the evidence in cancer care, which is why it becomes multidisciplinary. The pathologist says what the tumour is. The radiologist maps how far it has spread. Surgeons judge whether it can be removed; medical and radiation oncologists argue over sequencing. And nursing, pharmacy, rehabilitation, genetics, nutrition or palliative-care professionals may each spot a risk that changes what is realistic.

Those perspectives pay off only when they converge on one explicit clinical question. A room full of experts working from an incomplete file still produces an incomplete recommendation.

Distinguish Three Services That May Be Called “MDT”

Tumour board meeting

Specialists meet, usually without the patient, to review the evidence and agree on options or record them. NCI defines tumour board review as a regular treatment-planning process involving cancer doctors and other health professionals for new or complex cases.[1]

Multidisciplinary clinic

Here the patient does attend and may see several professionals in one day. The team can share information, but how the visit is run varies; ask whether a formal case conference took place and whether you get the outcome in writing.

Multiple specialist opinions

Several doctors look at the case separately. That can help, but it only becomes a tumour board once the opinions are reconciled into one joint record.

So ask which format the hospital is actually offering, whether the patient joins any part of it, and who handles the final conversation.

Start With One Decision Question

Asking a tumour board to “review everything” gets you nowhere. Frame it as a decision, for example:

Is the tumour resectable now, or should systemic therapy come first?
Does the pathology support the diagnosis assumed in the current plan?
Is local treatment appropriate for limited metastatic disease?
Which treatment intent—curative, disease-controlling or symptom-focused—is realistic?
Is a new biopsy needed before choosing a targeted or immune therapy?
How should frailty, organ function, fertility or a competing illness change the plan?

China’s National Health Commission has pushed single-disease, multidisciplinary care for complex cancer cases, and it names oncology, surgery, radiotherapy, pathology, pharmacy, imaging, laboratory medicine and nuclear medicine among the relevant disciplines.[2]

Who needs to be in the room follows from the question, not from a fixed cast of “five experts.” A sarcoma case may call for a specialist pathologist and a musculoskeletal radiologist. A liver tumour case may need hepatobiliary surgery and interventional radiology. A frail patient may need geriatrics and supportive care.

Make Sure the Case Is Ready for Discussion

Before the meeting, the coordinator should send round a structured case packet:

confirmed or working diagnosis and tumour type;
pathology report and whether source slides were reviewed;
current stage and the evidence used for it;
relevant DICOM imaging, not screenshots alone;
prior treatments, responses and toxicities;
performance status, organ function and major comorbidities;
medicines, allergies and infection or bleeding risks;
patient goals, constraints and decisions already declined;
exact question and deadline.

NCI notes that tumour review boards weigh pathology together with other tests when planning treatment.[6] If imaging or pathology was missing, the outcome should say so instead of implying a complete review.

Verify Who Was Present—and Who Was Missing

Ask for the participant list by specialty and role. Names help, but functions matter more:

Role	Question contributed
Pathology	What is the tumour, and how certain is the classification?
Radiology / nuclear medicine	Where is disease present, and what remains uncertain?
Surgery	Is an operation technically and medically feasible?
Medical oncology	What systemic options fit this disease and patient?
Radiation oncology	Is radiation indicated, deliverable and how should it be sequenced?
Nursing / pharmacy	Can the plan be delivered safely and understood?
Rehabilitation / nutrition / palliative care	What function, symptom or support risks require action?

If a key specialty was missing, ask whether it submitted an opinion in advance or whether the case has to come back for another meeting.

Read the Recommendation as a Conditional Statement

A good MDT outcome reads something like this:

If pathology review confirms X and repeat imaging shows no Y, the team recommends A followed by B. If either condition fails, option C should be reconsidered.

That tells you far more than “MDT recommends surgery.” You can see the assumptions and the branch points.

The written record should cover:

decision question;
evidence reviewed and dates;
working diagnosis and stage;
treatment intent;
options considered, including no immediate treatment when relevant;
reasons for the preferred option;
material risks or disadvantages;
dissent or unresolved uncertainty;
tests needed before commitment;
responsible clinician and review date.

NHS England’s MDT guidance concentrates full meeting time on patients with complex needs.[4] Routine cases can reasonably go through a streamlined pathway, as long as protocols, exceptions and accountability are clear. What is not acceptable is letting “not discussed live” turn into “no one made a documented decision.”

Separate Team Advice From Patient Consent

The tumour board advises. The patient decides, after a proper clinical discussion. A recommendation written without the patient in the room may not yet reflect fertility plans, work, caregiving duties, religious values, tolerance for risk or a strong wish to avoid a particular outcome.

NICE’s shared-decision framework says individual needs, preferences and values have to be weighed alongside the evidence, especially when the options involve trade-offs.[5]

After the meeting, have the responsible clinician explain:

What is the team trying to achieve?
Which alternatives were reasonable?
What benefit is expected, and how uncertain is it?
What harms, burdens and irreversible consequences matter?
What happens if the patient waits or declines?
Which part of the recommendation changes with the patient’s priorities?

If someone uses the phrase “the MDT decided” to close this conversation, push back.

Plan an International Case Before Travel

Ask whether the hospital will review the case remotely and what needs translating. Send the original reports together with the translations, and confirm which imaging and pathology files were actually imported into their system.

Then pin down the service boundary:

Is the fee for file screening, formal tumour board review or a patient-facing consultation?
Will a signed report be issued?
Can the patient submit questions?
Does the recommendation reserve an appointment or bed?
What changes after physical examination in China?
Who answers the home oncologist?

Sometimes the board’s answer saves an unnecessary trip; sometimes it flags one missing biopsy that should be done first. Either way, showing up in China is not proof that the team has already accepted the proposed treatment.

Know When the Case Should Return to the Board

The case may need to go back to the board when:

pathology or stage changes;
a required biomarker returns;
the patient does not respond as expected;
treatment causes toxicity that alters the risk–benefit balance;
surgery reveals different findings;
the patient’s health or goals change;
a clinical trial or new option becomes relevant;
the team’s conditional assumptions are no longer true.

The first report should name these triggers. Without that, “MDT follow-up” is a vague promise with nobody responsible for it.

Audit the Plan, Not Just the Meeting

The National Health Commission’s tumour-MDT pilot was meant to improve standardised diagnosis and treatment and patient safety.[3] Those goals live or die on what happens after the meeting.

For each action, write down:

Action	Owner	Due date	Completion evidence
Pathology review			Final report
Additional imaging			Images and signed interpretation
Patient decision visit			Consent or documented choice
Treatment booking			Date and service line
Supportive-care referral			Appointment or plan
Home-team handover			Sent and acknowledged

A recommendation that never reaches the patient, or that no one can carry out, is not coordinated care.

Questions to Ask About an MDT Service

What cases does this tumour board cover?
Which core specialties attend, and how often?
Will my pathology and imaging be formally reviewed?
What clinical question will be presented?
Will the written outcome show uncertainty and alternatives?
Who explains it to me in my language?
Can my home oncologist receive or discuss the report?
What triggers re-discussion?
Is the fee separate from consultations and tests?
Who tracks whether actions actually happen?

Medical disclaimer: Tumour-board review is a planning process. It is not a diagnosis, a guarantee or a substitute for informed consent. The treating clinician must apply the recommendation to the patient’s current condition and preferences. If the patient deteriorates urgently, get an immediate clinical assessment — do not wait for the next scheduled meeting.

Related guides

Pathology Review Before Cancer Treatment in China
Getting a Cancer Second Opinion in China
How to Share CT, MRI and Other Imaging Files With a Chinese Hospital
How to Find a Clinical Trial in China
How to Request an Itemized Treatment Cost Estimate

FAQ

Does the patient attend a tumour board meeting?

Usually not. Tumour boards are clinician meetings; multidisciplinary clinics are the format that may include the patient.[1] Ask which one is being offered and who will explain the outcome to you.

Does an MDT recommendation mean the treatment is definitely correct?

No. It reflects the evidence and expertise available at that moment. Missing material, new results or the patient’s own preferences can all change the plan.

Can an international case be discussed before travel?

Sometimes. The hospital has to confirm that it accepts remote records and whether pathology and DICOM imaging can be formally reviewed. An administrative file check is a different, lesser service.